This article is more than 5 years old. Information may no longer be current.

Alcon to acquire Optonol, enter surgical glaucoma market

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon has entered into a definitive agreement to acquire Optonol, Alcon announced in a press release.

With the acquisition, Alcon will obtain Optonol's Ex-PRESS mini glaucoma shunt, marking the company's entrance into the surgical glaucoma market.

The device, which is currently approved and available in the United States, Europe, Canada and Australia, is reimbursable through Medicare and other payers, and was assigned to CPT code 0192T by the American Medical Association in 2008.

"The acquisition of Optonol is part of our strategy to bolster organic growth with targeted investments in key therapeutic areas that have the potential to contribute in both the near and long term," Kevin Buehler, Alcon president and CEO, said in the release. "Because the product is already approved in the United States and other major markets, it will begin contributing commercially in 2010."

The acquisition, which is expected to close by the end of the first quarter of 2010, is dependent on customary closing conditions and the delivery of required regulatory approvals.